← Therapy pipeline
Investigational · Obesity development

AZD9550 + lenbelintide

AZD9550 + AZD6234 · AstraZeneca

Amylin plus GLP-1/glucagon co-administration; its own Phase 2 program.

GLP-1glucagonamylin
Obesity stagePhase 2Updated as of November 2026
SponsorAstraZeneca
TargetsGLP-1 + glucagon + amylin
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Results availability

No numerical results shown

No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagonTargeted
AMYamylinTargeted
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 2Initiated
Milestone → next

Latest: The Phase 2 ASCEND obesity study is completed; results are pending.

Next: Phase 2b efficacy and safety results.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies1 record